Black Fungus in India: 45,374 Cases and 4,300+ Deaths by July 2021

Facebook ↗WhatsApp ↗

Originally published 2021-07-26.

By late July 2021, India's government had recorded 45,374 cases of mucormycosis, the infection nicknamed "black fungus", and more than 4,300 deaths. Almost all of the cases followed a bout of COVID-19, and the surge came in the weeks after the country's devastating second wave in April and May 2021. Maharashtra, India's second most populous state, reported the most cases, more than 9,000 on its own.

India's Mucormycosis Death Figures Reported in July 2021

Those numbers describe a specific moment, two months into an outbreak that doctors had never seen on this scale. Below is what the figures meant, what mucormycosis actually is, why India was hit so hard, and why physicians warned that the official count was almost certainly too low.

What the July 2021 figures showed

The national totals were presented to India's parliament on 20 July 2021 by junior health minister Bharati Pravin Pawar. According to AFP's report of that session, the government's data suggested infections had peaked in May and June and then fallen substantially. Before the pandemic, the country saw only a small number of recognised cases each year, so tens of thousands in two months was an extraordinary jump.

In May, as hospitals filled with patients, the central government asked states to treat the disease as an epidemic, and several, Rajasthan among them, formally declared it one. That step made reporting mandatory and helped officials track supplies of the main antifungal drug, which quickly ran short.

Dividing 4,300 deaths by 45,374 cases gives a figure of roughly 9.5%, and a mortality rate of around 10% circulated widely at the time. That simple ratio is misleading. Many patients were still being treated when the count was taken, and deaths that happen weeks later are easy to miss. Medical literature puts the death rate for the sinus-and-brain form of the disease far higher, at roughly half of cases even with treatment.

What mucormycosis is

Mucormycosis is caused by a group of moulds called Mucorales, most often species of Rhizopus and Mucor. Their spores are everywhere: in soil, compost, rotting leaves and animal dung. Healthy people breathe them in all the time without harm, because a working immune system clears them.

The trouble starts when the body's defences are weakened. The fungus then invades blood vessels, cutting off the supply to nearby tissue, which dies and turns dark. That dead, blackened tissue is where the nickname comes from. The mould itself is not black.

The form seen most in India affects the sinuses, the eye socket and, in the worst cases, the brain. Other forms attack the lungs, the gut or the skin. The disease does not pass from person to person.

Why COVID-19 patients in India were hit so hard

Indian health data from the end of June 2021 point clearly at the main risk factors. Of more than 40,000 confirmed cases at that point, about 85% had a history of COVID-19, about 64% had diabetes, and more than half had been given steroids.

Each of these matters:

  • Diabetes. India has one of the largest diabetic populations in the world, and many people do not know they have it. High blood sugar, and especially the acidic state called diabetic ketoacidosis, helps Mucorales grow.
  • Steroids. Drugs such as dexamethasone save lives in severe COVID-19 by calming an overactive immune response. They also raise blood sugar and lower immunity. Doctors said overuse, including in mild cases and at high doses, was a major driver.
  • The virus itself. Severe COVID-19 can damage the lining of blood vessels and disrupt the immune system, giving opportunistic infections an opening.
  • Environment. Spores are abundant in hot, humid conditions. Researchers have also floated the idea that burning dung and crop stubble may spread more spores, though this remains a hypothesis.

Some early reporting said the outbreak was happening nowhere else in the world. That was not quite right. COVID-linked cases were also reported in other countries, including Pakistan, Iran and Egypt. What set India apart was scale. Studies suggest the country's background rate of mucormycosis was already many times higher than in Western countries before the pandemic, roughly 70 to 80 times by some estimates.

Why the real toll was probably higher

Doctors treating patients doubted that the official numbers captured everything. Speaking to the BBC, Bengaluru eye surgeon Dr Raghuraj Hegde explained the gap in plain terms: "Typically, deaths in mucormycosis occur weeks to months after getting the disease. Our present systems are not good to capture that data."

He pointed to other blind spots too. Poorer patients in rural areas often live far from hospitals that can diagnose the infection, and during the second wave many hospitals had no free beds at all. People who never reached a specialist were never counted.

Recurrence was a second worry. Mumbai ophthalmologist Dr Akshay Nair told the BBC that patients who had been treated aggressively and sent home were coming back with the infection spreading further into the eye or brain. For families who believed the danger had passed, that was a cruel turn.

How it is diagnosed and treated

There is no simple blood test. Diagnosis usually needs a tissue sample, examined under the microscope and grown in a lab, supported by CT or MRI scans to see how far the infection has spread.

Treatment has three parts, and speed matters for all of them:

  • Antifungal drugs, with amphotericin B the first choice and isavuconazole or posaconazole as alternatives. In May and June 2021 India faced a severe shortage of amphotericin B and had to ramp up production and imports.
  • Surgery to remove dead and infected tissue. Because the fungus cuts off blood supply, drugs cannot reach some areas. Surgeons in India sometimes had to remove an eye or part of the jaw to stop the infection reaching the brain.
  • Controlling the underlying cause, especially bringing blood sugar back under control and reducing immune-suppressing drugs where possible.

Warning signs reported by health agencies include one-sided facial pain or swelling, a blocked or bloody nose, dark patches on the nose or the roof of the mouth, headache, a swollen or bulging eye and blurred vision. Anyone with these symptoms, particularly after COVID-19 or with diabetes, should talk to a doctor promptly.

Common myths about black fungus

"It is contagious." It is not. People catch it from spores in the environment, not from other patients.

"The fungus is black." The colour comes from dead tissue, not the mould. Labels such as "white fungus" and "yellow fungus" that appeared in Indian media in 2021 added confusion; doctors urged people to use the names of the actual infections instead.

"Everyone who had COVID-19 was at risk." The vast majority of people who had COVID-19 never developed mucormycosis. The danger was concentrated among people with uncontrolled diabetes, heavy steroid treatment or other serious immune problems.

"Poor sanitation alone explains it." Spores are common in nature everywhere, including in very clean settings. Hospital outbreaks elsewhere in the world have been linked to things like contaminated linen or building work. In India the combination of diabetes, steroids and severe COVID-19 matters far more than hygiene on its own.

What the outbreak taught

The black fungus surge was a reminder that a pandemic's harm does not stop at the virus. Treatments that save lives in intensive care need careful dosing and follow-up, and patients with diabetes need their blood sugar watched closely during and after hospital stays.

It also showed how hard it is to count deaths during a health emergency. When hospitals are overwhelmed and illness strikes weeks after discharge, official tallies trail behind reality. The July 2021 figure of more than 4,300 deaths is best read as a minimum, not a final total.

Sources: Arab News / AFP: India records more than 45,000 cases of black fungus (21 July 2021); Wikipedia: Mucormycosis. Original reporting and doctors' quotes: BBC News.

COMMENTS